Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 413


Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects.

Coleman JR, Moore EE, Zilberman-Rudenko J, Samuels JM, Cohen MJ, Silliman CC, Banerjee A, Sauaia A, Griffin JH, Deguchi H.

Shock. 2019 Nov;52(5):554-555. doi: 10.1097/SHK.0000000000001426.


Molecular interaction site on procoagulant myosin for factor Xa-dependent prothrombin activation.

Deguchi H, Guo Z, Hayat M, Pflimlin E, Lear S, Shen W, Griffin JH.

J Biol Chem. 2019 Oct 11;294(41):15176-15181. doi: 10.1074/jbc.AC119.010236. Epub 2019 Sep 3.


Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis.

Müller-Calleja N, Hollerbach A, Ritter S, Pedrosa DG, Strand D, Graf C, Reinhardt C, Strand S, Poncelet P, Griffin JH, Lackner KJ, Ruf W.

Blood. 2019 Oct 3;134(14):1119-1131. doi: 10.1182/blood.2019001530. Epub 2019 Aug 21.


Rapid Communication: Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects.

Coleman JR, Moore EE, Zilberman-Rudenko J, Samuels JM, Cohen MJ, Silliman CC, Banerjee A, Sauaia A, Griffin JH, Deguchi H.

Shock. 2019 Jul 30. doi: 10.1097/SHK.0000000000001426. [Epub ahead of print]


Templated Synthesis of End-Functionalized Graphene Nanoribbons through Living Ring-Opening Alkyne Metathesis Polymerization.

von Kugelgen S, Piskun I, Griffin JH, Eckdahl CT, Jarenwattananon NN, Fischer FR.

J Am Chem Soc. 2019 Jul 17;141(28):11050-11058. doi: 10.1021/jacs.9b01805. Epub 2019 Jul 2.


Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells.

Sinha RK, Flynn R, Zaiken M, Paz K, Gavin AL, Nemazee D, Fernández JA, Xu X, Griffin JH, Blazar BR.

Blood. 2019 Aug 29;134(9):776-781. doi: 10.1182/blood.2019001259. Epub 2019 Jun 26.


Neuroprotection and vasculoprotection using genetically targeted protease-ligands.

Rajput PS, Lamb JA, Fernández JÁ, Bai J, Pereira BR, Lei IF, Leung J, Griffin JH, Lyden PD.

Brain Res. 2019 Jul 15;1715:13-20. doi: 10.1016/j.brainres.2019.03.010. Epub 2019 Mar 14.


3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice.

Lazic D, Sagare AP, Nikolakopoulou AM, Griffin JH, Vassar R, Zlokovic BV.

J Exp Med. 2019 Feb 4;216(2):279-293. doi: 10.1084/jem.20181035. Epub 2019 Jan 15.


Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.

Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN Jr, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Clarke Haley E, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Mark Haacke E, Fawaz M, Davis TP, Toga AW, Griffin JH, Zlokovic BV; NeuroNEXT Clinical Trials Network NN104 Investigators.

Ann Neurol. 2019 Jan;85(1):125-136. doi: 10.1002/ana.25383. Epub 2019 Jan 7.


Design of a DNA-Programmed Plasminogen Activator.

Mukherjee P, Leman LJ, Griffin JH, Ghadiri MR.

J Am Chem Soc. 2018 Nov 14;140(45):15516-15524. doi: 10.1021/jacs.8b10166. Epub 2018 Nov 1.


Activated protein C, protease activated receptor 1, and neuroprotection.

Griffin JH, Zlokovic BV, Mosnier LO.

Blood. 2018 Jul 12;132(2):159-169. doi: 10.1182/blood-2018-02-769026. Epub 2018 Jun 4. Review.


Regulation of immune cell signaling by activated protein C.

Healy LD, Rigg RA, Griffin JH, McCarty OJT.

J Leukoc Biol. 2018 Mar 30. doi: 10.1002/JLB.3MIR0817-338R. [Epub ahead of print] Review.


SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity.

Gupta N, Liu R, Shin S, Sinha R, Pogliano J, Pogliano K, Griffin JH, Nizet V, Corriden R.

J Antimicrob Chemother. 2018 Jun 1;73(6):1586-1594. doi: 10.1093/jac/dky033.


α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Martos L, Ramón LA, Oto J, Fernández-Pardo Á, Bonanad S, Cid AR, Gruber A, Griffin JH, España F, Navarro S, Medina P.

Thromb Haemost. 2018 Apr;118(4):630-638. doi: 10.1055/s-0038-1629902. Epub 2018 Feb 15.


The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia.

Gupta N, Sinha R, Krasnodembskaya A, Xu X, Nizet V, Matthay MA, Griffin JH.

Stem Cells. 2018 May;36(5):796-806. doi: 10.1002/stem.2796. Epub 2018 Feb 14.


PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.

Sinha RK, Wang Y, Zhao Z, Xu X, Burnier L, Gupta N, Fernández JA, Martin G, Kupriyanov S, Mosnier LO, Zlokovic BV, Griffin JH.

Blood. 2018 Mar 15;131(11):1163-1171. doi: 10.1182/blood-2017-10-810895. Epub 2018 Jan 17.


Targeting anticoagulant protein S to improve hemostasis in hemophilia.

Prince R, Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N, Suardi S, Amini P, Fernández JA, Burnier L, Quarroz C, Reina Caro MD, Matsumura Y, Kremer Hovinga JA, Griffin JH, Simon HU, Ibba-Manneschi L, Saller F, Calzavarini S, Angelillo-Scherrer A.

Blood. 2018 Mar 22;131(12):1360-1371. doi: 10.1182/blood-2017-09-800326. Epub 2018 Jan 9.


Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S.

Fernández JA, Xu X, Sinha RK, Mosnier LO, Sanner MF, Griffin JH.

Blood Adv. 2017 Aug 7;1(18):1423-1426. doi: 10.1182/bloodadvances.2017007005. eCollection 2017 Aug 8.


Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases.

Deguchi H, Navarro S, Payne AB, Elias DJ, Dowling NF, Austin HD, España F, Medina P, Hooper WC, Griffin JH.

Res Pract Thromb Haemost. 2017 Jul;1(1):33-40. doi: 10.1002/rth2.12018. Epub 2017 Jun 23.


Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.

Deguchi H, Elias DJ, Griffin JH.

Res Pract Thromb Haemost. 2017 Jul;1(1):93-102. doi: 10.1002/rth2.12017. Epub 2017 Jun 20.


Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.

Amar AP, Sagare AP, Zhao Z, Wang Y, Nelson AR, Griffin JH, Zlokovic BV.

Neuropharmacology. 2018 May 15;134(Pt B):293-301. doi: 10.1016/j.neuropharm.2017.09.021. Epub 2017 Sep 18. Review.


Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.

Nazir S, Gadi I, Al-Dabet MM, Elwakiel A, Kohli S, Ghosh S, Manoharan J, Ranjan S, Bock F, Braun-Dullaeus RC, Esmon CT, Huber TB, Camerer E, Dockendorff C, Griffin JH, Isermann B, Shahzad K.

Blood. 2017 Dec 14;130(24):2664-2677. doi: 10.1182/blood-2017-05-782102. Epub 2017 Sep 7.


F-group bZIPs in barley-a role in Zn deficiency.

Nazri AZ, Griffin JHC, Peaston KA, Alexander-Webber DGA, Williams LE.

Plant Cell Environ. 2017 Nov;40(11):2754-2770. doi: 10.1111/pce.13045. Epub 2017 Sep 19.


Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo.

Healy LD, Puy C, Fernández JA, Mitrugno A, Keshari RS, Taku NA, Chu TT, Xu X, Gruber A, Lupu F, Griffin JH, McCarty OJT.

J Biol Chem. 2017 May 26;292(21):8616-8629. doi: 10.1074/jbc.M116.768309. Epub 2017 Apr 13.


2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

Griffin JH, Mosnier LO, Fernández JA, Zlokovic BV.

Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2143-2151. Epub 2016 Oct 6. Review.


3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice.

Wang Y, Zhao Z, Rege SV, Wang M, Si G, Zhou Y, Wang S, Griffin JH, Goldman SA, Zlokovic BV.

Nat Med. 2016 Sep;22(9):1050-5. doi: 10.1038/nm.4154. Epub 2016 Aug 22.


Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va.

Deguchi H, Sinha RK, Marchese P, Ruggeri ZM, Zilberman-Rudenko J, McCarty OJT, Cohen MJ, Griffin JH.

Blood. 2016 Oct 6;128(14):1870-1878. doi: 10.1182/blood-2016-03-707679. Epub 2016 Jul 15.


Physiological cerebrovascular remodeling in response to chronic mild hypoxia: A role for activated protein C.

Burnier L, Boroujerdi A, Fernández JA, Welser-Alves JV, Griffin JH, Milner R.

Exp Neurol. 2016 Sep;283(Pt A):396-403. doi: 10.1016/j.expneurol.2016.07.004. Epub 2016 Jul 10.


Activated protein C promotes neuroprotection: mechanisms and translation to the clinic.

Griffin JH, Fernández JA, Lyden PD, Zlokovic BV.

Thromb Res. 2016 May;141 Suppl 2:S62-4. doi: 10.1016/S0049-3848(16)30368-1. Review.


Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis.

Alsultan A, Gale AJ, Kurban K, Khalifah M, Albadr FB, Griffin JH.

Thromb Res. 2016 Jul;143:17-21. doi: 10.1016/j.thromres.2016.04.011. Epub 2016 Apr 23.


Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism.

Deguchi H, Banerjee Y, Elias DJ, Griffin JH.

J Atheroscler Thromb. 2016 Oct 1;23(10):1159-1167. Epub 2016 May 9.


Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.

Gale AJ, Bhat V, Pellequer JL, Griffin JH, Mosnier LO, Von Drygalski A.

Pharm Res. 2016 Jun;33(6):1517-26. doi: 10.1007/s11095-016-1895-3. Epub 2016 Mar 9.


Apolipoprotein E Receptor 2 Mediates Activated Protein C-Induced Endothelial Akt Activation and Endothelial Barrier Stabilization.

Sinha RK, Yang XV, Fernández JA, Xu X, Mosnier LO, Griffin JH.

Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):518-24. doi: 10.1161/ATVBAHA.115.306795. Epub 2016 Jan 21.


Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Bhat V, von Drygalski A, Gale AJ, Griffin JH, Mosnier LO.

Thromb Haemost. 2016 Mar;115(3):551-61. doi: 10.1160/TH15-07-0525. Epub 2015 Oct 15.


Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke.

Amar AP, Griffin JH, Zlokovic BV.

Front Cell Neurosci. 2015 Sep 2;9:344. doi: 10.3389/fncel.2015.00344. eCollection 2015. Review.


Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Liang HP, Kerschen EJ, Basu S, Hernandez I, Zogg M, Jia S, Hessner MJ, Toso R, Rezaie AR, Fernández JA, Camire RM, Ruf W, Griffin JH, Weiler H.

Blood. 2015 Nov 19;126(21):2415-23. doi: 10.1182/blood-2015-05-644401. Epub 2015 Sep 4. Erratum in: Blood. 2018 May 31;131(22):2509.


Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex.

Yegneswaran S, Banerjee Y, Fernández JA, Deguchi H, Griffin JH.

PLoS One. 2015 Aug 11;10(8):e0135025. doi: 10.1371/journal.pone.0135025. eCollection 2015.


Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation.

Banno F, Kita T, Fernández JA, Yanamoto H, Tashima Y, Kokame K, Griffin JH, Miyata T.

Blood. 2015 Nov 5;126(19):2247-53. doi: 10.1182/blood-2015-06-653162. Epub 2015 Aug 6.


Inhibition of thrombin generation in human plasma by phospholipid transfer protein.

Deguchi H, Wolfbauer G, Cheung MC, Banerjee Y, Elias DJ, Fernández JA, Albers JJ, Griffin JH.

Thromb J. 2015 Jul 16;13:24. doi: 10.1186/s12959-015-0054-0. eCollection 2015.


Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data.

Deguchi H, Banerjee Y, Trauger S, Siuzdak G, Kalisiak E, Fernández JA, Hoang L, Tran M, Yegneswaran S, Elias DJ, Griffin JH.

Blood. 2015 Sep 24;126(13):1595-600. doi: 10.1182/blood-2015-03-636761. Epub 2015 Jul 14.


Activated protein C: biased for translation.

Griffin JH, Zlokovic BV, Mosnier LO.

Blood. 2015 May 7;125(19):2898-907. doi: 10.1182/blood-2015-02-355974. Epub 2015 Mar 30. Review.


EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.

Liang HP, Kerschen EJ, Hernandez I, Basu S, Zogg M, Botros F, Jia S, Hessner MJ, Griffin JH, Ruf W, Weiler H.

Blood. 2015 Apr 30;125(18):2845-54. doi: 10.1182/blood-2014-11-610717. Epub 2015 Mar 2. Erratum in: Blood. 2018 May 31;131(22):2508.


Re-evaluation of the anticoagulant properties of high-density lipoprotein-brief report.

Fernandez JA, Deguchi H, Banka CL, Witztum JL, Griffin JH.

Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):570-2. doi: 10.1161/ATVBAHA.114.304938. Epub 2014 Dec 30.


Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Mosnier LO, Zlokovic BV, Griffin JH.

Thromb Haemost. 2014 Nov;112(5):883-92. doi: 10.1160/TH14-05-0448. Epub 2014 Sep 18. Review.


An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.

von Drygalski A, Bhat V, Gale AJ, Burnier L, Cramer TJ, Griffin JH, Mosnier LO.

PLoS One. 2014 Aug 15;9(8):e104304. doi: 10.1371/journal.pone.0104304. eCollection 2014.


Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.

von Drygalski A, Cramer TJ, Bhat V, Griffin JH, Gale AJ, Mosnier LO.

J Thromb Haemost. 2014;12(3):363-72. doi: 10.1111/jth.12489.


Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice.

Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, Wang Y, Zhong Z, Sullivan JS, Griffin JH, Cleveland DW, Zlokovic BV.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):E1035-42. doi: 10.1073/pnas.1401595111. Epub 2014 Mar 3.


Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids.

Deguchi H, Elias DJ, Trauger S, Zhang HM, Kalisiak E, Siuzdak G, Griffin JH.

Br J Haematol. 2014 May;165(3):409-12. doi: 10.1111/bjh.12720. Epub 2014 Jan 23. No abstract available.


Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution.

Deguchi H, Elias DJ, Griffin JH.

J Thromb Haemost. 2014 Jan;12(1):90-2. doi: 10.1111/jth.12446. No abstract available.


Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.

Lyden P, Levy H, Weymer S, Pryor K, Kramer W, Griffin JH, Davis TP, Zlokovic B.

Curr Pharm Des. 2013;19(42):7479-85.

Supplemental Content

Loading ...
Support Center